Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.

• Status: Completed
• Trial end date: 2020-03-12
• Target enrollment: 0
• Participant gender: All

Summary

The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B: Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University

Criteria

Inclusion Criteria:

Inclusion Criteria:

• Patients with age range 18-75 years.

• Patients with any known potentially malignant lesion confirmed histologically and clinically.

Exclusion Criteria:

• Patients with systemic illness.

• Patients received previous treatment for the condition.

• Current malignancy.

• Pregnant or lactating women.

• Hypersensitivity to the intervention.